(Q36062038)

11 August 2017

1 reference

title

Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis (English)

1 reference

cost-effectiveness analysis

11 August 2017

main subject

1 reference

1 reference

Michael T Nurmohamed

1

1 reference

11 August 2017

Ben A C Dijkmans

series ordinal

2

1 reference

11 August 2017

language of work or name

1 reference

1 January 2005

1 reference

11 August 2017

1 reference

11 August 2017

volume

65

1 reference

11 August 2017

issue

5

1 reference

11 August 2017

page(s)

661-694

1 reference

Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology

11 August 2017

cites work

1 reference

12 December 2020

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

12 December 2020

Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.

1 reference

12 December 2020

Pregnancy in inflammatory bowel disease: Effect of sulfasalazine and corticosteroids on fetal outcome

1 reference

12 December 2020

Effect of sulphasalazine on the radiological progression of rheumatoid arthritis

1 reference

12 December 2020

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

1 reference

12 December 2020

Methotrexate therapy in rheumatoid arthritis: 15 years experience.

1 reference

12 December 2020

Cost-effectiveness, cost-utility, and cost-benefit studies in rheumatology: a review of the literature, 2001-2002.

1 reference

12 December 2020

Rheumatoid arthritis. Treatment of early disease

1 reference

12 December 2020

Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment

1 reference

12 December 2020

Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): a decision analysis model

1 reference

12 December 2020

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

1 reference

12 December 2020

Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis

1 reference

12 December 2020

Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine

1 reference

12 December 2020

Guidelines for the management of rheumatoid arthritis: 2002 Update

1 reference

12 December 2020

Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis

1 reference

12 December 2020

Methotrexate in the treatment of rheumatoid arthritis; pilot study

1 reference

12 December 2020

Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone

1 reference

12 December 2020

Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept

1 reference

12 December 2020

Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis

1 reference

12 December 2020

Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study

1 reference

12 December 2020

Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide

1 reference

12 December 2020

A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis

1 reference

12 December 2020

Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole

1 reference

12 December 2020

The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms.

1 reference

12 December 2020

Consensus recommendations for the assessment and treatment of rheumatoid arthritis.

1 reference

12 December 2020

Cyclosporin for sulphasalazine-induced aplastic anaemia in a patient with early rheumatoid arthritis

1 reference

12 December 2020

Tolerability of enteric-coated sulphasalazine in rheumatoid arthritis: results of a co-operating clinics study

1 reference

12 December 2020

Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage

1 reference

12 December 2020

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

1 reference

12 December 2020

The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation.

1 reference

12 December 2020

A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis

1 reference

12 December 2020

Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone

1 reference

12 December 2020

Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial

1 reference

12 December 2020

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

12 December 2020

Adalimumab - a new TNF-alpha antibody for treatment of inflammatory joint disease

1 reference

12 December 2020

Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year randomised controlled trial

1 reference

12 December 2020

Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij

1 reference

12 December 2020

1 reference

12 December 2020

A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis

1 reference

12 December 2020

Modeling the lifetime costs of rheumatoid arthritis.

1 reference

12 December 2020

Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy

1 reference

12 December 2020

Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis

1 reference

12 December 2020

The incidence of cancer associated with the treatment of rheumatoid arthritis

1 reference

12 December 2020

Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha

1 reference

12 December 2020

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

1 reference

12 December 2020

Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study.

1 reference

12 December 2020

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

12 December 2020

Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group

1 reference

12 December 2020

Alternative methods for analysis of radiographic damage in a randomized, double blind, parallel group clinical trial comparing hydroxychloroquine and sulfasalazine

1 reference

12 December 2020

Long-term treatment of destructive rheumatoid arthritis with methotrexate

1 reference

12 December 2020

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

1 reference

12 December 2020

Methotrexate in rheumatoid arthritis. Indications, contraindications, efficacy, and safety

1 reference

12 December 2020

Case reports of heart failure after therapy with a tumor necrosis factor antagonist

1 reference

12 December 2020

Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation

1 reference

12 December 2020

Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C.

1 reference

12 December 2020

A long-term prospective study of the use of methotrexate in rheumatoid arthritis. Update after a mean of fifty-three months

1 reference

12 December 2020

Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications

1 reference

12 December 2020

COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention

1 reference

12 December 2020

Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis

1 reference

12 December 2020

Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines

1 reference

12 December 2020

An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline

1 reference

12 December 2020

Safety of tumour necrosis factor-alpha antagonists

1 reference

12 December 2020

Economic burden of rheumatoid arthritis: a systematic review

1 reference

12 December 2020

Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis

1 reference

12 December 2020

Methotrexate induced early onset pancytopenia in rheumatoid arthritis: drug allergy? Idiosyncrasy?

1 reference

12 December 2020

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

12 December 2020

Efficacy of low-dose methotrexate in rheumatoid arthritis

1 reference

12 December 2020

Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment

1 reference

12 December 2020

Renal effects of low dose methotrexate in rheumatoid arthritis.

1 reference

12 December 2020

Efficacy and safety of leflunomide in active rheumatoid arthritis

1 reference

12 December 2020

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

1 reference

12 December 2020

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

12 December 2020

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

12 December 2020

Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

1 reference

12 December 2020

Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate

1 reference

12 December 2020

Which component of sulphasalazine is active in rheumatoid arthritis?

1 reference

12 December 2020

A clinical and economic review of disease-modifying antirheumatic drugs

1 reference

12 December 2020

Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases

1 reference

12 December 2020

A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.

1 reference

12 December 2020

Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study

1 reference

12 December 2020

Etanercept: a review of its use in rheumatoid arthritis

1 reference

12 December 2020

Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs

1 reference

12 December 2020

Absorption, metabolism, and excretion of salicylazosulfapyridine in man

1 reference

12 December 2020

Leflunomide and rheumatoid arthritis: a systematic review of effectiveness, safety and cost implications

1 reference

12 December 2020

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

12 December 2020

Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: A retrospective study

1 reference

12 December 2020

Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group

1 reference

12 December 2020

A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.

1 reference

12 December 2020

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

12 December 2020

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group

1 reference

12 December 2020

Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis

1 reference

12 December 2020

How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS)

1 reference

12 December 2020

Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study.

1 reference

12 December 2020

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

12 December 2020

Inhibition of Protein Tyrosine Phosphorylation in T Cells by a Novel Immunosuppressive Agent, Leflunomide

1 reference

12 December 2020

Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression.

1 reference

12 December 2020

Comparison of rheumatoid arthritis care costs in patients starting therapy with leflunomide versus etanercept.

1 reference

12 December 2020

Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France.

1 reference

12 December 2020

Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis

1 reference

12 December 2020

Current treatment paradigms in rheumatoid arthritis

1 reference

12 December 2020

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

12 December 2020

Low dose pulse methotrexate therapy in rheumatoid arthritis.

1 reference

12 December 2020

Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis?

1 reference

12 December 2020

Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis

1 reference

12 December 2020

Systemic low-dose glucocorticoid treatment in rheumatoid arthritis

1 reference

12 December 2020

Treatment of chronic polyarthritis with low-dose methotrexate

1 reference

12 December 2020

Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis

1 reference

12 December 2020

Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey

1 reference

12 December 2020

Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production

1 reference

12 December 2020

Infliximab: a review of its use in the management of rheumatoid arthritis

1 reference

12 December 2020

Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years

1 reference

12 December 2020

A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis.

1 reference

12 December 2020

Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial

1 reference

12 December 2020

Economic consequences of the progression of rheumatoid arthritis in Sweden

1 reference

12 December 2020

Leflunomide: a manageable safety profile.

1 reference

12 December 2020

Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells

1 reference

12 December 2020

Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients

1 reference

12 December 2020

Toxicity of low dose methotrexate in rheumatoid arthritis.

1 reference

12 December 2020

Rheumatoid arthritis, methotrexate, and lymphoma: risk substitution, or cat and mouse with Epstein-Barr virus?

1 reference

12 December 2020

Clinical liver disease in patients with rheumatoid arthritis taking methotrexate

1 reference

12 December 2020

Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate

1 reference

12 December 2020

Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist

1 reference

12 December 2020

The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study

1 reference

12 December 2020

Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirt

1 reference

12 December 2020

Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans

1 reference

12 December 2020

Use of biologics for rheumatoid arthritis tempered by concerns over safety, cost

1 reference

12 December 2020

Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety

1 reference

12 December 2020

The use of sulphasalazine as a disease modifying antirheumatic drug

1 reference

12 December 2020

Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate

1 reference

12 December 2020

Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis.

1 reference

12 December 2020

Etanercept--infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFalpha

1 reference

12 December 2020

TNF-alpha and heart failure. The difference between proof of principle and hypothesis testing

1 reference

12 December 2020

Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice.

1 reference

12 December 2020

Methotrexate pulmonary toxicity

1 reference

12 December 2020

Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother

1 reference

12 December 2020

1 reference

12 December 2020

Addressing the safety of anakinra in patients with rheumatoid arthritis

1 reference

12 December 2020

Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months

1 reference

12 December 2020

Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial

1 reference

12 December 2020

Cytokine pathways and joint inflammation in rheumatoid arthritis

1 reference

12 December 2020

10.2165/00003495-200565050-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

11 August 2017

1000073507

0 references

1 reference